WHO ICTRP trial
Nivolumab and ipilimumab in patients with dMMR and/or MSI metastatic colorectal…
CTIS2024-516313-20-00 · EU Clinical Trials Information System · Recruiting
Key facts
| Trial ID | CTIS2024-516313-20-00 |
|---|---|
| Public title | Nivolumab and ipilimumab in patients with dMMR and/or MSI metastatic colorectal cancer resistant to anti-PD1 monotherapy: An open-label phase II GERCOR trial (NIPIRESCUE) |
| Scientific title | - NIPIRESCUE_G-113 |
| Primary sponsor | Association Gercor |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): No Therapeutic exploratory (Phase II): Yes Therapeutic confirmatory - (Phase III): No Therapeutic use - (Phase IV): No |
| Countries | France |
| Conditions | Metastatic colorectal cancer;Therapeutic area: Diseases [C] - Neoplasms [C04] |
| Registration date | Aug 23, 2024 |
| Target size | 30 |
| Secondary IDs | NCT05310643;2021-005146-15 |
| Registry page | euclinicaltrials.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: